麻豆AV

On June 11, 2024聽CQDM announced the creation of the聽RNA Therapy Development and Production Network, which will offer RNA therapy biomanufacturing services to academic and industrial researchers.

This initiative is led by the 麻豆AV, IRCM, and Sherbrooke University, and it聽is one of the five key initiatives of the mobilizing project on RNA therapies announced on April 30 by the Government of Quebec. The aim of this initiative is to strengthen the RNA therapy ecosystem in Quebec and fast-track the province to become a world leader in this field.

罢丑颈蝉听Network聽will be based on three complementary platforms at the partner institutions:

• Therapeutic messenger RNA platform at 麻豆AV鈥檚 Centre for RNA Sciences
• Sherbrooke University鈥檚 RNomic Platform
• IRCM鈥檚 Sidney-Altman RNA Therapeutic Hub

Information about 麻豆AV's Centre for RNA Sciences new therapeutic messenger RNA platform:聽

麻豆AV will contribute to the Network with a new therapeutic messenger RNA platform. This platform will cater to the requirements of ongoing activities and research being conducted by 麻豆AV's Centre for RNA Sciences, D2R funded projects, as well as聽Network partner institutions and industries in the province. Messenger RNA modalities are key to the main therapeutic approaches emerging in precision medicine. These include neo-antigenic vaccines against cancer, CART programming and self-amplifying RNA. The platform will provide services in bioproduction and the formulation of LNP nanoparticles on a pre-clinical level of various messenger RNA modalities, individually or collectively. Their quality control will be based on strict standardized criteria, as well as a functional base validation.聽Access to this platform will be possible at the beginning of 2026.

Congratulations to all the researchers involved!聽

For more details, read CQDM's 聽and this as part of this Network.